Gilead turns to Second Genome for microbiome-based biomarkers to guide stratification, combos

Gilead entered the microbiome space Monday via a partnership with Second Genome to discover biomarkers to guide clinical development of the pharma’s pipeline and identify IBD compounds.

Under the four-year deal, Second Genome Inc. will identify biomarkers associated with up to five compounds in the pipeline of Gilead Sciences Inc. (NASDAQ:GILD), including programs in inflammation, fibrosis and oncology, and up to five inflammatory bowel disease (IBD) candidates. ...